aTyr Pharma

aTyr Pharma’s stock rose in premarket trading after the company reported stronger-than-expected Q2 results and unveiled a comprehensive restructuring plan. The company posted a loss per share of $0.11 versus a consensus expectation of a $0.13 loss and plans to cut roughly 60% of its workforce to focus the pipeline on the candidate Efzofitimod. aTyr filed a Phase-3 protocol with the FDA in June and expects feedback by the end of August; enrollment for the Phase-2 EFZO‑CONNECT study is complete, with topline data targeted for Q1 2027. Management’s goal is to extend the cash runway to the end of 2028 to fund these milestones. » Więcej na de.investing.com

aTyr Pharma has filed a phase‑3 protocol with the FDA for efzofitimod to treat chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. A subgroup analysis of the phase‑2/3 study showed a placebo‑adjusted increase in forced vital capacity of 123.8 ml at 48 weeks for the 5.0 mg/kg dose, along with improvements in KSQ‑Lung, KSQ‑General Health, Fatigue Assessment Scale and Leicester Cough Questionnaire. The planned phase‑3 trial lists FVC as the primary endpoint and KSQ‑Lung as the key secondary endpoint. Financials show negative free cash flow of $59.3 million over the last twelve months, while a current ratio of 5.78 points to more liquid assets than liabilities; the shares trade at $0.49, well below the 52‑week high. » Więcej na de.investing.com

aTyr Pharma shares plunged about 15% in pre-market trading after announcing a new global phase-3 study of efzofitimod for pulmonary sarcoidosis. The company plans to file an IND in June 2026 and has incorporated FDA feedback from a Type C meeting. The randomized, double-blind, placebo-controlled study plans about 372 patients over 54 weeks with 5.0 mg/kg every three weeks; the primary endpoint is change in forced vital capacity (FVC), with the KSQ-Lung score as a key secondary endpoint. Earlier EFZO-FIT data showed a clinically meaningful benefit in FVC versus placebo in patients with restrictive lung disease. » Więcej na de.investing.com